CTMX CYTOMX THERAPEUTICS INC US FDA Inspections 8-K Filing 2024 - Other Special Situation CytomX Therapeutics, Inc. announced initial data from the ongoing CX-904 Phase 1a dose escalation clinical study.Get access to all SEC 8-K filings of the CYTOMX THERAPEUTICS INC